SCHEMBL4517192

SCHEMBL4517192

CCOC(=O)c1sc2nc(Nc3ccccc3)[nH]c(=O)c2c1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.64
ALDH1A1 P00352 6/20 0.64
KMT2A Q03164 5/20 0.63
MEN1 O00255 4/20 0.63
PIP4K2A P48426 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
MAPT P10636 7/20 0.53
HPGD P15428 3/20 0.53
RAB9A P51151 2/20 0.53
GAA P10253 2/20 0.53
LMNA P02545 1/20 0.53
NPC1 O15118 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
PKM P14618 1/20 0.51
RXFP1 Q9HBX9 2/20 0.50
DHODH Q02127 1/20 0.50
PPARG P37231 1/20 0.50
NCOA2 Q15596 1/20 0.50
ADORA3 P0DMS8 1/20 0.49
ADORA2A P29274 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492121 0.87 ADORA3 (0.55) KDM4EALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL4525636 0.81 KMT2A (0.66) KDM4EALDH1A1KMT2AMEN1PIP4K2A
SCHEMBL4519694 0.80 KMT2A (0.64) KDM4EALDH1A1KMT2AMEN1PIP4K2A
SCHEMBL18406168 0.79 KDM4E (0.98) KDM4EALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL4519596 0.79 KMT2A (0.71) KDM4EALDH1A1KMT2AMEN1PIP4K2A
SCHEMBL4564998 0.79 KMT2A (0.71) KDM4EALDH1A1KMT2AMEN1PIP4K2A
SCHEMBL4520199 0.79 KMT2A (0.63) KDM4EALDH1A1KMT2AMEN1PIP4K2A
SCHEMBL4528944 0.78 KMT2A (0.70) KDM4EALDH1A1KMT2AMEN1PIP4K2A
SCHEMBL4520492 0.78 KMT2A (0.62) KDM4EALDH1A1KMT2AMEN1PIP4K2A
SCHEMBL4565171 0.78 KMT2A (0.70) KDM4EALDH1A1KMT2AMEN1PIP4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 KDM4E 2859/4885ALDH1A1 2303/4885KMT2A 2650/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 KDM4E 2859/4885ALDH1A1 2303/4885KMT2A 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.